Evidence map›Paper›PMID 38987177›Full record

ArticleBiological & pharmaceutical bulletin2024

Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3.

Kohei Tsuji, Hirokazu Tamamura, Terrence R Burke

Abstract read
In one paragraph

Article in Biological & pharmaceutical bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kohei TsujiChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health.
Hirokazu TamamuraDepartment of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University.
Terrence R BurkeChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health.

Funding

INHIBITORS OF TYROSINE-SPECIFIC PROTEIN KINASES AS ANTICANCER AGENTSZ01BC006198 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BURKE, TERRENCE · 1996 to 2008
$1.6M
Intramural NIH HHS Z01 BC006198
6 · The paper itself

Abstract

Assay systems for evaluating compound protein-binding affinities are essential for developing agonists and/or antagonists. Targeting individual members of a protein family can be extremely important and for this reason it is critical to have methods for evaluating selectivity. We have previously reported a fluorescence recovery assay that employs a fluorescein-labelled probe to determine IC

Indexed as

Cell Cycle ProteinsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsFluorescenceHumansPolo-like KinasesProtein BindingProtein Kinase InhibitorsPteridinesTumor Suppressor ProteinsBI 2536Cell Cycle ProteinsPLK2 protein, humanPLK3 protein, humanPolo-Like Kinase 1Polo-like KinasesProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesTumor Suppressor Proteinsfluorescence recovery assaykinase selectivityPlk2Plk3polo-like kinase 1 (Plk1)

Identifiers

PMID38987177
PMCPMC12349913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.